HOOK (HOOK) 24-hour amplitude 43.7%: Slight rebound after panic selling triggered by Binance delisting announcement
Bitget Pulse2026/03/21 19:51Volatility Brief
Over the past 24 hours, HOOK has experienced extreme price volatility, with a high of $0.0194, a low of $0.0135, and a current price of $0.0152, resulting in an amplitude of 43.7%. The 24-hour trading volume is approximately $9.16 million, which is higher than its $4.32 million market cap (volume-to-market cap ratio exceeds 211%), indicating significant net capital outflows driven by panic sentiment.
Brief Analysis of the Reason for the Abnormal Movement
- Binance announced it will delist HOOK and other tokens on April 1, 2026, directly triggering panic selling within 24 hours, with the price plunging more than 35% from its peak and dropping to around $0.0138 at its lowest point.
- Trading volume surged above $9 million, accompanied by liquidity sweeps and selling pressure, causing volatility to reach as much as 43.7%, followed by a short-term rebound of about 7-11%.
Market View and Outlook
Overall, market sentiment remains bearish. The community is pessimistic about the delisting event, believing that short-term rebounds will be limited and a support test at $0.014 is possible. Most traders are focused on short-term rebound strategies, but warn that if the support is lost, prices could fall further. Mainstream platform data show developer activity is lacking, with risk warnings centered on liquidity contraction after delisting.
Note: This analysis is auto-generated by AI based on public data and on-chain monitoring and is for informational reference only.Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight
Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.
Eli Lilly (LLY.US) "lowers its stance" and joins forces with former rival Hims (HIMS.US) to compete for the self-pay weight loss drug market
Eli Lilly is collaborating with Hims & Hers Health, leveraging the telehealth company’s large customer base to expand access to its blockbuster weight loss drugs and boost sales of medications, including its new oral weight loss drug Foundayo.
"Predicting Your Prediction" Intensifies Tech Stock Sell-off! After $2.3 Trillion Market Value Evaporates, Has the "Hot Money" Mechanical Selling Still Not Subsided?
The Nasdaq 100 Index fell by 6.4%, wiping out $2.3 trillion in market capitalization. The core reason behind this decline is concerns that a comprehensive victory by the Democratic Party could lead to stricter regulations on AI development. Systematic funds, which typically follow the stock market's trend and respond to price fluctuations and momentum signals, were thus forced to reduce their investments, accelerating the downturn. The selling pressure from systematic strategies may not be over yet; it is expected that in the coming days, portfolios targeting volatility will sell at least $50 billion worth of stocks.
The midterm election tears open the "abyss" of AI trading, facing a moment of reckoning for trillion-dollar capital expenditure narratives
For months, investors have been worried about a series of risks behind the AI (artificial intelligence) capital expenditure "money tree." This week, the market finally pressed the panic selling button.
Crypto prices
More
